Evidence map›Paper›PMID 38728430›Full record

ArticleBlood2024

The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma.

Anthony M Cirrincione, Alexandra M Poos, Bachisio Ziccheddu, Marcella Kaddoura, Marc-Andrea Bärtsch, Kylee Maclachlan, Monika Chojnacka, Benjamin Diamond, Lukas John, Philipp Reichert and 19 more

Abstract read
In one paragraph

Article in Blood, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors.

Anthony M CirrincioneMyeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
Alexandra M PoosHeidelberg Myeloma Center, Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
Bachisio ZicchedduMyeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
Marcella KaddouraMyeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
Marc-Andrea BärtschHeidelberg Myeloma Center, Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
Kylee MaclachlanMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-7873-4854
Monika ChojnackaMyeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.ORCID 0000-0001-7176-6108
Benjamin DiamondMyeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.ORCID 0000-0002-8638-9365
Lukas JohnHeidelberg Myeloma Center, Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.ORCID 0000-0001-8178-6890
Philipp ReichertClinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center, Heidelberg, Germany.
Stefanie HuhnClinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center, Heidelberg, Germany.
Patrick BlaneyMyeloma Research Program, New York University Langone, Perlmutter Cancer Center, New York, NY.ORCID 0000-0002-9319-8866
Dylan GaglerMyeloma Research Program, New York University Langone, Perlmutter Cancer Center, New York, NY.
Karsten RippeDivision of Chromatin Networks, German Cancer Research Center and BioQuant, Heidelberg, Germany.ORCID 0000-0001-9951-9395
Yanming ZhangCytogenetics Laboratory, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
Ahmet DoganHematopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-6576-5256
Alexander M LesokhinMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-9321-702X
Faith DaviesMyeloma Research Program, New York University Langone, Perlmutter Cancer Center, New York, NY.
Hartmut GoldschmidtDepartment of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.ORCID 0000-0003-0961-0035
Roland FenkDepartment of Hematology, Oncology and Clinical Immunology, University-Hospital Duesseldorf, Duesseldorf, Germany.
Katja C WeiselDepartment of Oncology, Hematology, and Blood and Marrow Transplant, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Elias K MaiDepartment of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.ORCID 0000-0002-6226-1252
Neha KordeMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-5538-4318
Gareth J MorganMyeloma Research Program, New York University Langone, Perlmutter Cancer Center, New York, NY.
Saad UsmaniMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Ola LandgrenMyeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.ORCID 0000-0001-6485-4839
Marc S RaabHeidelberg Myeloma Center, Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
Niels WeinholdHeidelberg Myeloma Center, Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
Francesco MauraMyeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.ORCID 0000-0002-5017-1620

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1M
Tumor Biology Research ProgramP30CA240139 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Daniel Bilbao · 2019 to 2026
$24.1M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016087NCI NIH HHS P30 CA240139
6 · The paper itself

Abstract

abstractAcquisition of a hyperdiploid (HY) karyotype or immunoglobulin heavy chain (IgH) translocations are considered key initiating events in multiple myeloma (MM). To explore if other genomic events can precede these events, we analyzed whole-genome sequencing data from 1173 MM samples. By integrating molecular time and structural variants within early chromosomal duplications, we indeed identified pregain deletions in 9.4% of patients with an HY karyotype without IgH translocations, challenging acquisition of an HY karyotype as the earliest somatic event. Remarkably, these deletions affected tumor suppressor genes (TSGs) and/or oncogenes in 2.4% of patients with an HY karyotype without IgH translocations, supporting their role in MM pathogenesis. Furthermore, our study points to postgain deletions as novel driver mechanisms in MM. Using multiomics approaches to investigate their biologic impact, we found associations with poor clinical outcome in newly diagnosed patients and profound effects on both the oncogene and TSG activity despite the diploid gene status. Overall, this study provides novel insights into the temporal dynamics of genomic alterations in MM.

Indexed as

Multiple MyelomaChromosome AberrationsFemaleGene DeletionGenes, Tumor SuppressorHumansImmunoglobulin Heavy ChainsMaleTranslocation, GeneticImmunoglobulin Heavy Chains

Identifiers

PMID38728430
PMCPMC11375460

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.